|
|
||||||||
Departments of 1 Internal Medicine, 2 Pediatrics, and 3 Anesthesia, Cardiovascular and Clinical Research Centers, University of Iowa College of Medicine and Veterans Affairs Medical Center, Iowa City, Iowa 52242
| |
ABSTRACT |
|---|
|
|
|---|
The exact mechanisms for the decrease in R-R interval (RRI) during acute physiological hyperinsulinemia with euglycemia are unknown. Power spectral analysis of RRI and microneurographic recordings of muscle sympathetic nerve activity (MSNA) in 16 normal subjects provided markers of autonomic control during 90-min hyperinsulinemic/euglycemic clamps. By infusing propranolol and insulin (n = 6 subjects), we also explored the contribution of heightened cardiac sympathetic activity to the insulin-induced decrease in RRI. Slight decreases in RRI (P < 0.001) induced by sevenfold increases in plasma insulin could not be suppressed by propranolol. Insulin increased MSNA by more than twofold (P < 0.001), decreased the high-frequency variability of RRI (P < 0.01), but did not affect the absolute low-frequency variability of RRI. These results suggest that reductions in cardiac vagal tone and modulation contribute at least in part to the reduction in RRI during hyperinsulinemia. Moreover, more than twofold increases in MSNA occurring concurrently with a slight and not purely sympathetically mediated tachycardia suggest regionally nonuniform increases in sympathetic activity during hyperinsulinemia in humans.
insulin; muscle sympathetic nerve activity
| |
INTRODUCTION |
|---|
|
|
|---|
STUDIES IN NORMAL HUMANS have shown that acute
physiological increases in plasma insulin in the absence of changes in
blood glucose cause opposing sympathoexcitation and vasodilatation in the skeletal muscle vascular bed (2, 3). Furthermore, hyperinsulinemia increases heart rate and cardiac output, which may be secondary to the
peripheral vasodilator actions of insulin (2, 3, 6, 28). The
insulin-induced increase in heart rate may be caused by increased
cardiac sympathetic outflow but also by cardiac vagal withdrawal. A
previous study in animals (9) suggested that chronic hyperinsulinemia
is accompanied by reduced cardiac vagal activity. The exact mechanisms
of insulin-induced increases in heart rate have thus far not been
assessed in humans. Spectral analysis of R-R interval (1, 30) and
-adrenergic receptor blockade during a hyperinsulinemic/euglycemic
clamp could be used to address this issue.
R-R interval discloses cyclic variations related to the respiratory cycle called respiratory sinus arrhythmia or high-frequency (HF) variability (1, 30). In addition, R-R interval discloses also low-frequency (LF) oscillations, and changes in the amplitude of these cyclic variations provide markers of cardiac vagal and sympathetic modulation (1, 10, 23, 25, 30). In the present study, we performed a hyperinsulinemic/euglycemic clamp in normal human volunteers and measured heart rate, blood pressure, and respiration. R-R interval variability was determined by power spectral analysis.
The insulin-induced changes in HF variability of R-R interval were assessed to test the hypothesis that hyperinsulinemia decreases cardiac vagal modulation.
We also administered a continuous intravenous infusion of propranolol,
a
-adrenergic receptor blocker, during the
hyperinsulinemic/euglycemic clamp to determine if increased cardiac
sympathetic outflow contributed to the increase in heart rate induced
by insulin.
In addition, animal studies have suggested that insulin may produce nonuniform increases in sympathetic activity (20), and changes in cardiac sympathetic activity during hyperinsulinemia were compared with those present in direct recordings of sympathetic nerve traffic to muscle circulation.
| |
METHODS |
|---|
|
|
|---|
Subjects. We studied 16 subjects with a mean age of 31 ± 1 (SE) yr (5 males, 11 females) and a mean body mass index of 24 ± 1 kg/m2. All subjects were healthy and had blood pressures <130/80 mmHg measured on three different occasions in the sitting position.
None was receiving any medication. The study was approved by the Institutional Human Subjects Review Committee, and written informed consent was obtained.
Measurements. Blood pressures were measured with an automatic sphygmomanometer (Lifestat 200; Physio-Control, Redmond, WA). Electrocardiogram and respiration (Biotach and Pneumotrace; Gould Electronics, Valley View, OH) were recorded on all subjects. Forearm blood flow was measured by venous occlusion plethysmography using air-filled latex cuffs. Intraneural recordings of muscle sympathetic nerve activity (MSNA) were obtained from leg microneurographic recordings of multiunit postganglionic sympathetic fibers, measured in the peroneal nerve posterior to the fibular head (19, 34). We used tungsten microelectrodes (shaft diameter 200 µm, tapering to an uninsulated tip of 1-5 µm). A subcutaneous reference electrode was inserted 2-3 cm away from the recording electrode inserted in the nerve fascicle. The neural signals were amplified, filtered, rectified, and integrated to obtain a mean voltage display of sympathetic nerve activity. All nerve recordings met standard criteria (19, 34).
Electrocardiogram, sympathetic neurogram, and respiration were recorded on a Macintosh Quadra 900 Computer (Apple Computer, Cupertino, CA) with a MacLab 8/s data acquisition system (AD Instruments, Milford, MA).
These measurements were also recorded on an IBM 433DX/T computer. All subjects were breathing spontaneously and were not allowed to speak during the study.
Spectral analysis. Analog-to-digital conversion was performed online at 1,000 samples/s for the electrocardiogram and at 200 samples/s for the respiratory signal. Stationary segments devoid of arrhythmias and artifacts (150-300 s) were then analyzed offline with a personal computer (IBM 433DX/T).
The principles of the software for data acquisition and spectral analysis have been described elsewhere (21, 22, 27). A discrete Fourier transformation (CARSPAN 1.0; Faculty of Psychology, University of Groningen, Groningen, The Netherlands) with a spectral resolution of 0.01 Hz was applied to the time series of R-R interval. A respirogram synchronized with the tachogram was also obtained by sampling the signal of respiratory activity once every cardiac cycle.
Absolute power spectral density functions (ms2) were computed for R-R interval in the 0.02- to 0.50-Hz band (total variability), in the very-low-frequency (VLF) band (0.02-0.03 Hz), in the LF band (0.04-0.14 Hz), and in the HF band (0.15-0.35 Hz).
The respirogram underwent a similar analysis to the one described above.
Hyperinsulinemic/euglycemic clamp. Insulin (Humulin; Eli Lilly, Indianapolis, IN) diluted in saline with 1 ml of the subject's blood was infused intravenously by a digital infusion pump (Bard Medsystems, North Reading, MA). A hyperinsulinemic/euglycemic clamp over 90 min was performed as previously described (2, 3). Insulin infusion rates were targeted to produce plasma insulin levels of 85 µU/ml. Fasting plasma glucose levels were maintained by variable 20% dextrose infusion using an infusion pump (Flo-gard 6200; Travenol Laboratories, Deerfield, IL).
Plasma glucose and insulin were determined every 5 min. Plasma glucose was analyzed by a YSI glucose analyzer (model 27; Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin levels were determined by radioimmunoassay (35).
Protocol. All studies were started at 7:30 AM after an overnight fast. Subjects were placed in the supine position and instrumented for measurement of heart rate, blood pressure, and respiration. Intravenous catheters were placed in the right and left antecubital fossae for insulin/glucose infusion and blood sampling, respectively. The right arm was instrumented for forearm blood flow measurement. After an acceptable sympathetic nerve recording site was achieved, 10 min of baseline measurements were obtained before performing the 90-min hyperinsulinemic/euglycemic clamp.
We repeated 90-min hyperinsulinemic/euglycemic clamps during a continuous infusion of propranolol in 6 of the 16 normal subjects. We wanted thereby to determine if increased cardiac sympathetic outflow and/or cardiac vagal withdrawal contribute to the reduction in R-R interval during hyperinsulinemia. Measurements were performed during a 10-min baseline period before an intravenous injection of 5 mg of propranolol (26). A continuous infusion of 80 µg/min of propranolol was then started (26) and continued throughout the protocol, namely a baseline period of 20 min and a 90-min hyperinsulinemic/euglycemic clamp.
Vehicle control studies were performed in six normal subjects (5 males, mean age 28 ± 3 yr, mean body mass index 26 ± 2 kg/m2) in whom 0.2% saline was infused in a comparable volume to the insulin session.
Data analysis. Measurements were analyzed in a blinded fashion during 10 min of baseline recordings and during the last 15 min of the hyperinsulinemic/euglycemic clamp or vehicle session. Sympathetic bursts were identified by inspection of the mean voltage neurogram. MSNA was expressed as frequency (bursts/min) and as integrated activity (burst frequency × mean amplitude). The intra- and interobserver variability in burst identification in our laboratory are 4.3 ± 0.3 and 5.4 ± 0.5%, respectively (4, 19). Forearm blood flow was expressed as milliliters per minute per 100 milliliters of forearm volume. Mean arterial pressure was calculated as diastolic pressure plus one-third pulse pressure. Forearm vascular resistance was calculated by dividing mean arterial pressure by flow and is expressed in arbitrary units (AU).
Statistical analysis. Statistical analysis consisted of two-tailed Wilcoxon tests. Values are expressed as means ± SE. Significance was assumed at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Hyperinsulinemic/euglycemic clamp. Fasting plasma insulin levels averaged 12 ± 2 µU/ml. Steady-state plasma insulin concentrations were achieved after 30 min of insulin infusion, averaging 84 ± 5 µU/ml.
The baseline plasma glucose level of 85 ± 2 mg/dl did not change
significantly during insulin infusion [89 ± 2 mg/dl at 90 min, P = not significant (NS)].
R-R interval decreased from 1,047 ± 49 to 949 ± 45 ms after 90 min of insulin infusion (P < 0.001; Fig. 1 and Table
1). Insulin increased forearm blood flow
from 2.1 ± 0.2 to 3.4 ± 0.4 ml · min
1 · 100 ml
1
(P < 0.01; Fig. 1). Mean blood
pressure was 85 ± 3 mmHg during baseline and 85 ± 3 mmHg after
90 min of insulin infusion. Consequently, insulin infusion decreased
baseline forearm vascular resistance of 46 ± 5 units to 31 ± 4 units at the end of the clamp (P < 0.01; Fig. 1). Insulin also caused a marked increase in mean
sympathetic nerve activity (MSNA) from 208 ± 36 U/min (15 ± 2 bursts/min) at baseline to 433 ± 76 U/min (25 ± 2 bursts/min)
during insulin (both P < 0.001; Fig.
1).
|
|
Insulin decreased the absolute HF variability of R-R interval (P < 0.01; Fig. 2 and Table 1). This was not due to a change in the respiratory pattern during insulin, since respiratory rate was 0.29 ± 0.01 Hz during baseline and 0.28 ± 0.01 Hz during insulin (P = NS). Moreover, qualitative assessment of minute ventilation by the use of the pneumograph suggested that tidal volume increased during hyperinsulinemia as respiratory power increased from 6.5 ± 1.2 AU2 during baseline to 9.6 ± 2.2 AU2 during insulin infusion (P < 0.05) in the absence of changes in respiratory rate. The HF respiratory variability accounted for 84 ± 1 and 82 ± 3% of the respiratory power during baseline and insulin infusion, respectively (P = NS). Insulin did not affect the absolute VLF and LF variabilities of the R-R interval.
|
Propranolol.
-Blockade increased
the baseline R-R interval from 1,103 ± 42 to 1,213 ± 27 ms
(P < 0.05, Table
2). Mean blood pressure and
forearm vascular resistance remained unchanged. Propranolol did not
suppress the decrease in R-R interval induced by insulin. R-R interval
decreased from 1,213 ± 27 ms during the infusion of propranolol to
1,146 ± 33 ms (P < 0.05) during the last 15 min of infusion of insulin and propranolol.
Mean blood pressure was 81 ± 2 mmHg during the infusion of
propranolol and 78 ± 2 mmHg at the end of the infusion of insulin
and propranolol (P < 0.05). Forearm
vascular resistance was 41 ± 5 units during the infusion of
propranolol and decreased to 31 ± 3 units at the end of the
infusion of insulin and propranolol (P < 0.05).
|
Vehicle control studies. R-R interval
was 1,072 ± 65 ms during baseline and 1,077 ± 80 ms during the
last 15 min of vehicle infusion (P = NS). Vehicle did not affect forearm blood flow (2.5 ± 0.4 ml · min
1 · 100 ml
1 during baseline and 2.5 ± 0.3 ml · min
1 · 100 ml
1 during vehicle,
P = NS) and forearm vascular
resistance (38 ± 6 units during baseline and 39 ± 5 units
during vehicle, P = NS). Mean blood
pressure was 85 ± 3 mmHg during baseline and was 89 ± 3 mmHg
during the last 15 min of vehicle infusion
(P = 0.03). However, vehicle did not
affect MSNA. MSNA was 269 ± 42 U/min (20 ± 1 bursts/min) at
baseline and 261 ± 61 U/min (16 ± 3 bursts/min) at the end of
vehicle infusion (P = NS). R-R
interval variability remained unchanged during vehicle infusion. In
particular, the absolute HF variability of R-R interval was 1,229 ± 444 ms2 during baseline and 3,742 ± 2,901 ms2 during vehicle
infusion (P = NS).
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we determined the effects of insulin on the variability of R-R interval. Our study reveals that insulin decreases cardiac vagal tone since the reduction in R-R interval induced by insulin could not be abolished by propranolol. Moreover, insulin decreased also the absolute HF variability of R-R interval but did not affect the absolute LF variability of R-R interval. The HF variability of R-R interval is a marker of cardiac vagal modulation (10, 14, 16, 17, 25) and can be affected by changes in the respiratory-related vagal modulation of R-R interval (breathing pattern; see Refs. 10, 14, 16, 17, 32). However, respiratory rate remained unchanged, and qualitative assessment of respiration suggested that tidal volume increased during hyperinsulinemia, as a possible consequence of increased oxygen consumption during sympathetic hyperactivity (33). Thus our study reveals that reductions in the HF variability in R-R interval were not due to smaller tidal volumes during hyperinsulinemia (10, 14, 16, 17, 32) and that insulin decreased not only cardiac vagal tone but also cardiac vagal modulation.
Previous studies on heart rate variability during hyperinsulinemia (7,
11) neither recorded MSNA nor administered a
-adrenergic receptor
blocker during hyperinsulinemic/euglycemic clamps. In contrast, our
study reveals that propranolol does not abolish the decrease in R-R
interval induced by insulin and that insulin increases heart rate only
by 6 beats/min at a time when sympathetic drive to muscle circulation
is increased by more than twofold. Thus our results suggest that a
reduction in cardiac vagal tone contributed at least in part to the
small increase in heart rate during hyperinsulinemia and that insulin
produces differential increases in sympathetic activity in humans.
These results support previous observations in animals in which insulin
increased lumbar but not renal sympathetic nerve activity (20) and in
humans in which insulin increased sympathetic nerve activity to muscle but not to skin (8). This finding could also explain why heart rate
remained unchanged during hyperinsulinemia in the study of Bellavere et
al. (7) and increased only by two beats per minute in the study of
Emdin et al. (11).
Insulin sympathoexcitatory effects are mediated at least in part by a central neural action and possibly by baroreflex mechanisms secondary to peripheral vasodilatation (28). Increased sympathetic drive during hyperinsulinemic-euglycemic clamps is primarily targeted at the skeletal muscle vasculature. In addition, there is evidence that insulin selectively stimulates blood flow and decreases vascular resistance in skeletal muscle, chiefly by potentiation of endothelium-dependent vasodilatation and attenuation of sympathetic vasoconstriction (28). Accordingly, blood pressure did not change during hyperinsulinemia in our study as a result of opposing pressor and depressor actions of insulin in the skeletal vasculature. We also reported similar small changes in blood pressure during hyperglycemic/euglycemic clamps in two previous studies (2, 3). Regionally nonuniform increases in sympathetic drive opposing the vasodilatory action of insulin (2, 3, 28, 29) could explain why more than twofold increases in sympathetic nerve activity to muscle circulation were not accompanied by the expected increases in blood pressure.
Perspectives
The continuing difficulty with research on acute effects of increases in insulin on autonomic control is to establish relevance to the chronic hyperinsulinemia of obesity (33). There are, however, several studies that also suggest that cardiac vagal outflow is decreased, in the absence of a heightened cardiac sympathetic outflow, during chronic hyperinsulinemia. First, there is recent evidence of nonuniform sympathetic activation in obese subjects in whom cardiac sympathetic activity, directly assessed by norepinephrine spillover techniques, is depressed (33). Second, sequential parasympathetic blockade with atropine and sympathetic blockade with esmolol have revealed that weight gain impairs more cardiac parasympathetic control than cardiac sympathetic control in nonobese and obese subjects (5). Third, similar direct evidence of increased heart rate as a result of cardiac parasympathetic withdrawal rather than increased sympathetic stimulation was also found in obese dogs (31). Last, two other studies in which heart rate variability provided indirect measures of cardiac autonomic control also concluded that heart rate increases as a result of parasympathetic withdrawal when body weight increases (15, 24).Thus our data may provide a mechanistic explanation for previous observations of cardiac parasympathetic withdrawal in the absence of cardiac sympathetic activation in obese hyperinsulinemic subjects. The exact mechanisms by which obesity may have differential effects on cardiac sympathetic and vagal control are unknown. It is believed that central nervous mechanisms for sympathetic activation in obesity may reside in the hypothalamus (33), with neuropeptide Y being an important neurotransmitter (33, 13) that also possesses vagal inhibitory capacities (36).
Finally, there is indirect evidence that decreased cardiac vagal activity precedes onsets of ventricular tachycardia (12), and it is therefore tempting to speculate that insulin-induced cardiac vagal withdrawal might contribute to the increased cardiovascular mortality of obesity.
In conclusion, this study suggests that acute physiological elevations in plasma insulin decrease cardiac vagal tone and modulation and that insulin produces regionally nonuniform increases in muscle and cardiac sympathetic activity in humans.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Christine Sinkey for excellent research support and are indebted to Nancy Davin and Françoise Pignez for expert typing of this manuscript.
| |
FOOTNOTES |
|---|
This study was supported by National Institutes of Health Grants RR-0059 and HL-43514 and by Veterans Affairs Merit Review research funds.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests: P. van de Borne, Hypertension Clinic, Dept. of Cardiology, Erasme Hospital, 808 Lennik Rd., 1070 Brussels, Belgium.
Received 3 April 1998; accepted in final form 31 August 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Akselrod, S.,
D. Gordon,
F. A. Ubel,
D. C. Shannon,
A. C. Barger,
and
R. J. Cohen.
Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat to beat cardiovascular control.
Science
213:
220-222,
1981
2.
Anderson, E. A.,
T. W. Balon,
R. P. Hoffman,
C. A. Sinkey,
and
A. L. Mark.
Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans.
Hypertension
19:
621-627,
1992
3.
Anderson, E. A.,
R. P. Hoffman,
T. W. Balon,
C. A. Sinkey,
and
A. L. Mark.
Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.
J. Clin. Invest.
87:
2246-2252,
1991.
4.
Anderson, E. A.,
C. A. Sinkey,
W. J. Lawton,
and
A. L. Mark.
Elevated sympathetic nerve activity in borderline hypertensive humans.
Hypertension
14:
177-183,
1989
5.
Arone, L. J.,
R. Mackintosh,
M. Rosenbaum,
R. L. Leibel,
and
J. Hirsch.
Autonomic nervous system activity in weight gain and weight loss.
Am. J. Physiol.
269 (Regulatory Integrative Comp. Physiol. 38):
R222-R225,
1995
6.
Baron, A. D.,
and
G. Brechtel.
Insulin differentially regulates systemic and skeletal muscle vascular resistance.
Am. J. Physiol.
265 (Endocrinol. Metab. 28):
E61-E67,
1993
7.
Bellavere, F.,
V. Cacciatori,
P. Moghetti,
M. L. Gemma,
A. Dellera,
F. Tosi,
C. Negri,
K. Thomaseth,
and
M. Muggeo.
Acute effect of insulin on autonomic regulation of the cardiovascular system.
Diabet. Med.
13:
709-714,
1996[Medline].
8.
Berne, C.,
J. Faqius,
T. Pollare,
and
P. Hjemdahl.
The sympathetic response to euglycemic hyperinsulinaemia: evidence from microelectrode nerve recordings in healthy subjects.
Diabetologia
35:
873-879,
1992[Medline].
9.
Bunag, R. D.,
D. Krizsan,
and
H. Itoh.
Diminished cardiovascular responsiveness to vagal stimulation in obese rats.
Am. J. Physiol.
259 (Regulatory Integrative Comp. Physiol. 28):
R842-R848,
1990
10.
Eckberg, D. L.
Sympathovagal balance. A critical appraisal.
Circulation
96:
3224-3232,
1997
11.
Emdin, M.,
E. Muscelli,
C. Carpeggiani,
A. Natali,
C. Catalano,
S. Camastra,
E. Ferrannini,
and
A. L'Abbate.
Effect of insulin on sympatho-vagal balance in lean and obese subjects (Abstract).
Eur. Heart J.
18:
111,
1997.
12.
Fei, L.,
D. J. Statters,
K. Hnatkova,
J. Poloniecki,
M. Malik,
and
A. J. Camm.
Change of autonomic influence on the heart immediately before the onset of spontaneous idiopathic ventricular tachycardia.
J. Am. Coll. Cardiol.
24:
1515-1522,
1994[Abstract].
13.
Gray, T. S.,
and
J. E. Morley.
Neuropeptide Y: anatomical distribution and possible function in mamalian nervous system.
Life Sci.
38:
389-401,
1986[Medline].
14.
Hayano, J.,
S. Mukai,
M. Sakakibara,
A. Okada,
K. Takata,
and
T. Fujinami.
Effects of respiratory interval on vagal modulation of heart rate.
Am. J. Physiol.
267 (Heart Circ. Physiol. 36):
H33-H40,
1994
15.
Hirsch, J.,
R. L. Leibel,
R. Mackintosh,
and
A. Aguirre.
Heart rate variability as a measure of autonomic function during weight change in humans.
Am. J. Physiol.
261 (Regulatory Integrative Comp. Physiol. 30):
R1418-R1423,
1991
16.
Katona, P. G.,
and
F. Jih.
Respiratory sinus arrhythmia: noninvasive measure of parasympathetic control.
J. Appl. Physiol.
39:
801-805,
1975
17.
Malik, M.,
and
A. J. Camm.
Components of heart rate variability
what they really mean and what we really measure.
Am. J. Cardiol.
72:
821-822,
1993[Medline].
18.
Malliani, A.,
M. Pagani,
F. Lombardi,
and
S. Cerutti.
Cardiovascular neural regulation explored in the frequency domain.
Circulation
84:
1482-1492,
1991.
19.
Mark, A. L.,
R. G. Victor,
G. Nerhed,
and
B. G. Wallin.
Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans.
Circ. Res.
57:
461-469,
1985
20.
Morgan, D. A.,
T. W. Balon,
B. H. Ginsberg,
and
A. L. Mark.
Nonuniform regional sympathetic nerve response to hyperinsulinemia in rats.
Am. J. Physiol.
264 (Regulatory Integrative Comp. Physiol. 33):
R423-R427,
1993
21.
Mulder, L. J. M.
Measurement and analysis methods of heart rate and respiration for use in applied environments.
Biol. Psychol.
34:
205-236,
1992[Medline].
22.
Mulder, L. J. M.,
H. Van Dellen,
P. Van der Meulen,
and
S. B. Opheikens.
CARSPAN: a spectral analysis program for cardiovascular time series.
In: Proceedings of the Second Workshop on Computers in Psychology, edited by F. J. Maarse,
L. J. M. Mulder,
J. Sjouw,
and A. E. Akkerman. Lisse, The Netherlands: Swets en Zeitlinger, 1987, p. 30-38.
23.
Pagani, M.,
F. Lombardi,
S. Guzzetti,
O. Rimoldi,
R. Furlan,
P. Pizzinelli,
G. Sandrone,
G. Malfatto,
S. Dell'Orto,
E. Piccaluga,
M. Turiel,
G. Baselli,
S. Cerutti,
and
A. Malliani.
Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympathovagal interaction in man and conscious dog.
Circ. Res.
59:
178-193,
1986
24.
Patretta, M.,
D. Bonaduce,
E. de Filippo,
G. F. Mureddu,
L. Scalfi,
F. Marciano,
V. Bianchi,
L. Salemme,
G. de Simone,
and
F. Contaldo.
Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity.
Eur. J. Clin. Invest.
25:
826-832,
1995[Medline].
25.
Pomeranz, M.,
R. J. B. Macaulay,
M. A. Caudill,
I. Kutz,
D. Adam,
D. Gordon,
K. M. Kilborn,
A. C. Barger,
D. C. Shannon,
R. J. Cohen,
and
M. Benson.
Assessment of autonomic function in humans by heart rate spectral analysis.
Am. J. Physiol.
248 (Heart Circ. Physiol. 17):
H151-H153,
1985
26.
Rizza, A. R.,
P. E. Cryer,
and
J. E. Gerich.
Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation.
J. Clin. Invest.
64:
62-71,
1979.
27.
Robbe, H. W.,
L. J. Mulder,
H. Ruddel,
W. A. Langewitz,
J. B. Veldman,
and
G. Mulder.
Assessment of baroreceptor reflex sensitivity by means of spectral analysis.
Hypertension
10:
538-543,
1987
28.
Scherrer, U.,
and
C. Sartori.
Insulin as a vascular and sympathoexcitatory hormone. Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity.
Circulation
96:
4104-4113,
1997
29.
Steinberg, H. O.,
G. Brechtel,
A. Johnson,
N. Fineberg,
and
A. D. Baron.
Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent.
J. Clin. Invest.
94:
1172-1179,
1994.
30.
Task Force of the European Society of Cardiology.,
and
the North American Society of Pacing and Electrophysiology.
Heart rate variability. Standards of measurement, physiological interpretation, and clinical use.
Circulation
93:
1043-1065,
1996
31.
Truett, A. A.,
A. T. Borne,
M. A. Poincot,
and
D. B. West.
Autonomic control of blood pressure and heart rate in obese hypertensive dogs.
Am. J. Physiol.
270 (Regulatory Integrative Comp. Physiol. 39):
R541-R549,
1996
32.
Van de Borne, P.,
P. Biston,
M. Paiva,
H. Nguyen,
P. Linkowski,
and
J. P. Degaute.
Cardiorespiratory respiratory transfer during sleep: a study in young men.
Am. J. Physiol.
269 (Heart Circ. Physiol. 38):
H952-H958,
1995
33.
Vaz, M.,
G. Jennings,
A. Turner,
H. Cox,
G. Lambert,
and
M. Esler.
Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects.
Circulation
96:
3423-3429,
1997
34.
Wallin, G.
Intraneural recording and autonomic function in man.
In: Autonomic Failure, edited by R. Bannister. London: Oxford Univ. Press, 1983, p. 36-51.
35.
Yalow, R. S.,
and
S. A. Berson.
Immunoassay of endogenous plasma insulin in man.
J. Clin. Invest.
39:
1157-1175,
1960.
36.
Yang, T.,
and
M. N. Levy.
Sequence of excitation as a factor in sympathetic-parasympathetic interactions in the heart.
Circ. Res.
71:
898-905,
1992
This article has been cited by other articles:
![]() |
M. R. Carnethon, L. Yan, P. Greenland, D. B. Garside, A. R. Dyer, B. Metzger, and M. L. Daviglus Resting Heart Rate in Middle Age and Diabetes Development in Older Age Diabetes Care, February 1, 2008; 31(2): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sundell, P. Nuutila, H. Laine, M. Luotolahti, K. Kalliokoski, O. Raitakari, and J. Knuuti Dose-Dependent Vasodilating Effects of Insulin on Adenosine-Stimulated Myocardial Blood Flow Diabetes, April 1, 2002; 51(4): 1125 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Panzer, M. S. Lauer, A. Brieke, E. Blackstone, and B. Hoogwerf Association of Fasting Plasma Glucose With Heart Rate Recovery in Healthy Adults: A Population-Based Study Diabetes, March 1, 2002; 51(3): 803 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Furlan, A. Porta, F. Costa, J. Tank, L. Baker, R. Schiavi, D. Robertson, A. Malliani, and R. Mosqueda-Garcia Oscillatory Patterns in Sympathetic Neural Discharge and Cardiovascular Variables During Orthostatic Stimulus Circulation, February 29, 2000; 101(8): 886 - 892. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |